New Zealand Shareholders King Salmon Investments (NZSE: NZK) Down 26% On Their Shares | Instant News


Goldman Sachs: These 3 Shares Can Jump More Than 40%

Hope for good news on the near horizon is floating the market at this time. Over the past month, the S&P 500 and NASDAQ are up 11% to new record highs. Investors are excited about the prospect of an upcoming COVID vaccine before winter ends. And the election result, that Democrat Joe Biden will rise to the Presidency while the Republican Party will emerge strengthened in Congress, promises the extreme avoidance typical of a divided government. In short, investors look forward to a ‘back to normal’ environment over the next few months. And that leaves them looking for stocks that are ready to profit. Against this backdrop, Goldman Sachs analysts discussed three stocks in particular, noting that each of them could surge more than 40% in the coming year. After running both tickers through the TipRanks database, we found that the rest of Street was also standing right in the bull camp. Codiack BioSciences (CDAK) As we have learned from the Corona virus pandemic, some novelties in medical science can be overwhelming. impact on our world. Codiack aims to turn that principle into goodness. This research-oriented drug aims to transform exosome therapy into a new class of drugs. Exosomes are mechanisms of RNA degradation, and can transfer genetic material throughout the body, and therein lies the potential. Codiack has developed a design platform for engineering exosomal proteins capable of carrying and protecting drug molecules through cell walls. As a result, the proteins will mimic the pathways used by viruses – but not viruses, and are designed to carry a ‘payload’ of therapeutic agents. If successful, exosome therapy offers physicians the ability to design drugs that will deliver specific agents to specific cells to fight specific diseases.Codiack is involved in all aspects of exosome therapy, from design to manufacturing, and currently has active agent lines – seven, simultaneously. the whole – in the various stages of discovery, preclinical testing, and the initiation of Phase 1 trials. In the biosciences, success or failure is all about that pipeline, and in the diverse pipelines of active agents in the new sector of biotechnology in pharmaceuticals, Codiack has significant resources. good for attracting investors. To find these investors, the company went public last October, selling 5.5 million shares at an opening price of $ 14.10 per share. Among fans of the health care name is Goldman Sachs analyst Graig Suvannavejh. The analyst wrote, “The biopharma industry’s interest in exosomes has long been high, but engineering them for specific functions and manufacturing on a large scale has proven challenging. Among competitors, CDAK has made the most significant progress on both fronts, and we therefore view their technology platform as best in class. “” Given the stock’s underperformance (-37%) since the IPO, we find the risk / reward very attractive at current levels, and with the 2021 main data set to provide potential de-risking and positive stock inflection, “analysts said. conclude. Suvannavejh rated CDAK to Buy, and its $ 29 price target shows its confidence level – it implies a 222% increase for the coming year. (To see Suvannavejh’s track record, click here) Overall, Codiack has a Strong Buy by consensus of analysts – 3 reviewers have posted a Buy rating in the last few weeks. The stock is selling for $ 8.90, and the $ 24 median target price implies a potential one-year 166% gain. (See CDAK stock analysis at TipRanks) Arcutis Biotherapeutics (ARQT) Acrutis is a pioneering researcher in the treatment of dermatological diseases. Arcutis is involved in discovering the next generation of dermatological treatments – an important niche, especially when one realizes that one common disease, psoriasis, hasn’t received FDA approval for a new treatment for more than two decades. The company is leveraging recent advances in immunology and inflammation to find new approaches to skin care. Its aim is to make it easier for patients and physicians to jointly manage conditions such as psoriasis, alopecia, atopic dermatitis, seborrheic dermatitis, and vitiligo, to name but a few. The company’s lead candidate, ARQ-151 (roflumilast cream), is about to enter a phase 3 trial for atopic dermatitis, and in an advanced phase 3 trial in Plaque Psoriasis. Arcutis recently issued an update on positive data from the Phase 2 trial of ARQ-151 in atopic dermatitis. This medication is a once-daily treatment, and has shown significant patient relief from symptoms, especially sleep problems associated with itching and itching. This is another stock in the range of the Suvannavejh universe. Goldman analysts were impressed by developments in the company’s pipeline work, noting: “The ARQT provides an update on the results of its Phase 2 final meeting with the FDA, following the Phase 2a trial of ARQ-151 in atopic dermatitis (AtD). Feedback from regulators is broadly encouraging, in particular, acknowledging the strong long-term safety data generated by the ARQT for ARQ-151 in plaque psoriasis… ”Accordingly, Suvannavejh rated ARQT a Buy, and set a $ 36 price target showing room for 40% upward growth by 2021. To see Suvannavejh’s track record, click here) Arcutis has 2 reviews Recent buy, ranking consensus as Moderate Buy. Average share price target is $ 37, representing a 44% increase from current levels. (View stock analysis ARQT at TipRanks) Oak Street Health (OSH) With our last stock, we are moving from medical research to medical care Specifically, Oak Street Health is the clinic operator primary care services, and part of the Medicare Network. The company has operations and clinics in Illinois, Indiana, Michigan, Pennsylvania, and Ohio, along with New York, North Carolina, Rhode Island, Tennessee, and Texas. It has been in operation for eight years, and went public last summer, holding an IPO in August. In the third quarter, the first company as a public entity, OSH generated $ 217.9 million in revenue. The revenue figure is up 56% from last year’s quarter. Earnings per share was in line with expectations, which was 15 cents. The company’s expansion was rapid, and in October, Oak Street entered New York by opening, in Brooklyn, its 70th location. The planned expansion in Texas, which involves a partnership with Walmart, is also progressing as planned, and Oak Street has opened its first Walmart Community Clinic in the Dallas-Fort Worth area city of Carrollton. Robert Jones, who underwrote this stake for Goldman, set a $ 74 price target to support his Buy rating. At current levels, this target implies a ~ 58% increase in the next 12 months. (To see Jones’ track record, click here) “Results suggest operations are still on track, with some additional updates since the 2Q call, during which management noted the resumption of center openings, (rotating) marketing efforts, and in-person visits despite COVID. In 3Q, K3 opened 13 new centers and was on track for 73-75 by the end of the year… The company stated that they continue to operate at high levels in places with an increasing number of COVID cases such as Chicago and Detroit, ”said Jones. Overall, Strong Buy K3 consensus analyst rating is based on 8 reviews, divided into 7 Buy and Hold only. The stock is selling for $ 46.94, and the $ 61.29 median target price indicates that it has a ~ 31% gain for the year to come. (See OHS stock analysis at TipRanks) To find great ideas for trading health stocks with an eye-catching rating, visit TipRanks ‘Best Stocks to Buy, a recently launched tool that brings together all of TipRanks’ equity insights. Disclaimer: Opinions expressed in this article are those of top analysts only. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

image source

to request modification Contact us at Here or [email protected]